Cassava Sciences (NASDAQ:FLNA) CEO Buys $23,322.52 in Stock

Cassava Sciences, Inc. (NASDAQ:FLNA – Get Free Report) CEO Richard Barry acquired 44,851 shares of the business’s stock in a transaction that occurred on Wednesday, November 18th. The shares were purchased at an average price of $0.52 per share, with a total value of $23,322.52. Following the completion of the acquisition, the chief executive officer owned 1,955,947 shares of the company’s stock, valued at $1,017,092.44. This represents a 2.35% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Richard Barry also recently made the following trade(s):

  • On Wednesday, September 30th, Richard Barry purchased 100,000 shares of Cassava Sciences stock. The shares were bought at an average cost of $0.92 per share, for a total transaction of $92,000.00.
  • On Tuesday, September 29th, Richard Barry bought 206,813 shares of Cassava Sciences stock. The stock was purchased at an average price of $0.90 per share, for a total transaction of $186,131.70.
  • On Monday, September 28th, Richard Barry acquired 93,091 shares of Cassava Sciences stock. The stock was bought at an average price of $0.84 per share, with a total value of $78,196.44.

Cassava Sciences Stock Performance

Shares of NASDAQ FLNA opened at $0.56 on Friday. The stock’s fifty day moving average is $0.69 and its 200 day moving average is $1.27. Cassava Sciences, Inc. has a 52 week low of $0.39 and a 52 week high of $3.45.

Cassava Sciences (NASDAQ:FLNA – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.22) EPS for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Cassava Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 9th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Cassava Sciences presently has a consensus rating of “Hold” and a consensus price target of $5.00.

Read Our Latest Stock Report on FLNA

About Cassava Sciences

(Get Free Report)

Cassava Sciences, Inc. is a biotechnology company focused on developing treatments and diagnostic tools for Alzheimer’s disease. The company’s Nasdaq ticker is SAVA; FLNA does not correspond to Cassava Sciences. Its research has included simufilam, an investigational oral drug candidate studied for Alzheimer’s, and SavaDX, a blood-based diagnostic program. These are products under development, not approved treatments or tests. Founded in 1998 as Pain Therapeutics, the company adopted the Cassava Sciences name in 2018.

Recommended Stories

Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.